Literature DB >> 16183125

Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients.

Dianne H Kim1, Walter J Stark, Terrence P O'Brien, James D Dick.   

Abstract

PURPOSE: To measure the achievable perioperative aqueous concentration of the commercially available topically administered fourth generation fluoroquinolones, moxifloxacin 0.5% ophthalmic solution, and gatifloxacin 0.3% ophthalmic solution, and to correlate this concentration with the agents' biological efficacy in the aqueous humor of patients undergoing routine cataract surgery.
DESIGN: Prospective, randomized, parallel, double-masked, clinical trial. PARTICIPANTS: Fifty patients undergoing cataract extraction.
METHODS: Patients (n = 25) were given perioperative topical moxifloxacin 0.5% or topical gatifloxacin 0.3% (n = 25). One drop of antibiotic was administered every 10 minutes for 4 doses beginning 1 hour prior to surgery. Aqueous humor was sampled via paracentesis and antibiotic concentrations were determined using validated high performance liquid chromatography (HPLC) procedures. Dilution analyses were performed to determine the biological efficacy of the agents in the aqueous against Staphylococcus epidermidis, the most common cause of postcataract endophthalmitis. MAIN OUTCOME MEASURES: Aqueous humor antibiotic concentrations were measured using HPLC and microdilution bioassay techniques. Biological activity was measured as minimal inhibitory dilution and minimal bactericidal dilution.
RESULTS: Aqueous humor concentrations for moxifloxacin via HPLC analysis were 1.80 (+/-1.21) microg/ml, whereas those for gatifloxacin were 0.48 (+/-0.34) microg/ml. This 3.8-fold difference in aqueous humor antibiotic concentrations was statistically significant (P = 0.00003). Similarly, the biological dilution analysis of the aqueous humor samples showed that moxifloxacin attained an estimated activity of 2.1 microg/ml, whereas the gatifloxacin activity was approximately 0.4 mug/ml, which represented a 4.9-fold difference.
CONCLUSIONS: This study demonstrated that after topically administered perioperative antibiotics with cataract surgery, moxifloxacin 0.5% ophthalmic solution achieved a statistically significantly higher concentration in aqueous humor compared with gatifloxacin (P = 0.00003). Results from the broth dilution analysis showed that moxifloxacin 0.5% was biologically more active against S. epidermidis than gatifloxacin 0.3% in aqueous humor after topical application. There were no adverse events reported, and incision wounds healed quickly and as expected.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16183125     DOI: 10.1016/j.ophtha.2005.06.017

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  18 in total

Review 1.  [Therapy and prognosis of bacterial keratitis].

Authors:  W Behrens-Baumann; U Pleyer
Journal:  Ophthalmologe       Date:  2007-01       Impact factor: 1.059

2.  Ocular penetration and efficacy of levofloxacin using different drug-delivery techniques for the prevention of endophthalmitis in rabbit eyes with posterior capsule rupture.

Authors:  Takahiro Uda; Takashi Suzuki; Arisa Mitani; Yoshitaka Tasaka; Shiro Kawasaki; Tsuyoshi Mito; Yuichi Ohashi
Journal:  J Ocul Pharmacol Ther       Date:  2014-01-11       Impact factor: 2.671

3.  The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.

Authors:  Jose Benitez-Del-Castillo; Yves Verboven; David Stroman; Laurent Kodjikian
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 4.  Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

5.  Prophylactic intracameral cefazolin and postoperative topical moxifloxacin after cataract surgery: endophthalmitis risk reduction and safety results in a 16-year study.

Authors:  Carlos L Moser; Monica Lecumberri Lopez; Magela Garat; Montserrat Martín-Baranera
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-08-07       Impact factor: 3.117

6.  A comparison of moxifloxacin and levofloxacin topical prophylaxis in a fluoroquinolone-resistant Staphylococcus aureus rabbit model.

Authors:  Regis P Kowalski; Eric G Romanowski; Francis S Mah; Hiroshi Sasaki; Masamichi Fukuda; Y J Gordon
Journal:  Jpn J Ophthalmol       Date:  2008-07-27       Impact factor: 2.447

7.  Methicillin resistance and biofilm production of Staphylococcus epidermidis isolates from infectious and normal flora conjunctiva.

Authors:  Norma Fariña; Margarita Samudio; Letizia Carpinelli; Martin M Nentwich; Herminia Mino de Kaspar
Journal:  Int Ophthalmol       Date:  2016-09-10       Impact factor: 2.031

8.  The comparison of fluoroquinolones to nonfluoroquinolone antibacterial agents for the prevention of endophthalmitis in a rabbit model.

Authors:  Regis P Kowalski; Eric G Romanowski; Robert M Q Shanks; Francis S Mah
Journal:  J Ocul Pharmacol Ther       Date:  2012-08-27       Impact factor: 2.671

9.  New treatments for bacterial keratitis.

Authors:  Raymond L M Wong; R A Gangwani; Lester W H Yu; Jimmy S M Lai
Journal:  J Ophthalmol       Date:  2012-09-06       Impact factor: 1.909

10.  Efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components.

Authors:  Patrícia Abreu Ferreira da Cunha; Flavio Araujo Shinzato; Geraldine Trevisan Tecchio; Sarah La Porta Weber; Alexandre Brasil; Amaryllis Avakian
Journal:  Clinics (Sao Paulo)       Date:  2013-06       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.